Fondaparinux with unfractionated heparin during revascularization in acute coronary syndromes (FUTURA/OASIS 8): A randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux

American Heart Journal

Volumn 160, Issue 6, 2010, Pages

  Steg, Philippe Gabriel ^a,b,c   Mehta, Shamir ^d   Jolly, Sanjit ^d   Xavier, Denis ^e   Rupprecht, Hans Juergen ^f   Lopez Sendon, Jose Luis ^g   Chrolavicius, Susan ^d   Rao, Sunil V ^h   Granger, Christopher B ^h   Pogue, Janice ⁱ   Laing, Shiona ^j   Yusuf, Salim ^d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICHAT HOSPITAL   (France)

^d MCMASTER UNIVERSITY   (Canada)

^e ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^f Gesundheits und Pflegezentrum Russelsheim   (Germany)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h DUKE CLINICAL RESEARCH INSTITUTE   (United States)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j GLAXOSMITHKLINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; BOLUS INJECTION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; UNSTABLE ANGINA PECTORIS;

EID: 78650151854     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.07.037     Document Type: Article

References (19)

1. Anderson J.L. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST elevation myocardial infarction: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines Circ 116 2007 803 877
2. Braunwald E., Antman E., and Beasely J. ACC/AHA 2002 guidelines update for the management of subjects with unstable angina and non-ST-segment elevation myocardial infarction-summary article J Am Coll Cardiol 40 2002 1366 1374
3. Bassand J.P. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology EHJ 28 2007 1598 1660
4. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigator (OASIS 5 Investigators) Comparison of fondaparinux and enoxaparin in acute coronary syndromes N Engl J Med 354 2006 1464 1476
5. Mehta S.R., Granger C.B., and Eikelboom J.W. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention JACC 50 2007 1742 1751
6. The OASIS-6 Trial Group Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction. The OASIS-6 randomized trial JAMA 295 2006 1519 1530
7. Schlitt A., Rupprecht H.J., and Reindl I. In vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter-associated thrombus Coronary Art Dis 19 2008 279 284
8. White H.D., Kleiman N.S., and Mahaffey K.W. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial Am Heart J 152 2006 1042 1050
9. Montalescot G., White H.D., Gallo R. and STEEPLE investigators Enoxaparin versus unfarctionated heparin in elective percutaneous coronary intervention N Engl J Med 355 2006 1006 1017
10. Montalescot G., and Walenga J.M. Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants Clin Appl Thromb Hemost 2009 1 14
11. Silber S. Guidelines for percutaneous coronary interventions. The task force for percutaneous coronary interventions of the European Society of Cardiology EHJ 26 2005 804 847
12. King S.B., and Smith S.C. Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention Circ 2008;117 2007 261 295
13. Popma J.J. Antithrombotic therapy during percutaneous coronary intervention: the seventh ACCP conference on antithrombotic and thrombolytic therapy Chest 126 2004 576 599
14. Tolleson T.R. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention JACC 41 2003 386 393
15. Brener S.J. Relationship between activated clotting time and ischemic or hemorrhagic complications Circ 110 2004 994 998
16. Boccara A., Benamer H., and Juliard J.M. A randomized trial of a fixed high dose versus a weight-adjusted low dose of intravenous heparin during coronary angioplasty Eur Heart J 18 1997 631 635
17. Niccoli G., and Banning A.P. Heparin dose during percutaneous coronary intervention: how low dare we go? Heart 88 2002 331 334
18. Denardo S.J. Efficacy and safety of minimal dose (≤1000 Units) unfractionated heparin with abciximab in percutaneous coronary intervention Am J Cardiol 91 2003 1 5
19. Cutlip D.E., Windecker S., and Mehran R. Academic research consortium. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351